XRAY — Behind the Metastatic Breast Cancer Headlines

FORCE’s eXamining the Relevance of Articles for You: Metastatic Breast Cancer (XRAY: MBC) looks behind the cancer headlines to bring you reliable information about metastatic breast cancer research-related news and information. XRAY: MBC reviews metastatic breast cancer research, provides plain-language and in-depth summaries, links to clinical trials, summarizes current guidelines and rates how well the media covered each topic. XRAY: MBC was made possible by the generous support of Novartis. 

Metastatic Breast Cancer

Read the topics we are discussing this month

All XRAYS in Metastatic Breast Cancer

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Inherited mutations In metastatic breast cancer patients

Most relevant for: People with metastatic breast cancer

Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)

Relevance: Medium

Relevance

Research Timeline: Post Approval

Research Timeline

Guideline: FDA issues warning on CDK inhibitors

Most relevant for: People currently taking a CDK inhibitor

The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)

Relevance: High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Supportive care can improve quality of life for people with metastatic breast cancer

Most relevant for: People diagnosed with metastatic breast cancer

Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)

Relevance: High

Relevance

Strength of Science: High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients

Most relevant for: People with metastatic, hormone-positive, Her2-negative breast cancer

The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19) 

 

 

Relevance: Medium-High

Relevance

Strength of Science: High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: LGBTQ patients recommend improvements for their cancer care

Most relevant for: LGBTQ cancer patients and their healthcare providers.

Little is known about the cancer care experiences of lesbian, gay, bisexual, transgender and queer (LGBTQ) patients. This study looks at recommendations from the LGBTQ community for improving their cancer care. (6/20/19)

Relevance: High

Relevance

Research Timeline: Post Approval

Research Timeline

Guideline: FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer

Most relevant for: People with metastatic, triple-negative breast cancer

The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Smart drug shows promising results for treatment of metastatic triple-negative breast cancer

Most relevant for: People with metastatic, triple-negative breast cancer

We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is a combination of two different molecules: an antibody that targets certain types of cancer and delivers a chemotherapy drug that can kill cancer cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)

Relevance: Medium-High

Relevance

Research Timeline: Post Approval

Research Timeline

Guideline: Breast surgeons recommend genetic testing for all breast cancer patients

Most relevant for: Anyone diagnosed with breast cancer

Summary: 

The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Prevalence of BRCA founder mutations in Bahamian women

Most relevant for: Bahamanian women

Summary:

The Bahamas has the highest known frequency of BRCA mutations among people diagnosed with breast cancer. This study reviewed whether population-based BRCA testing (testing everyone regardless of family or personal history of cancer) would be an effective approach for finding mutation carriers in the Bahamas. (3/4/19)

Relevance: Low

Relevance

Research Timeline: Lab Research

Research Timeline

Article: Promise of a cure for cancer is too good to be true

Most relevant for: People diagnosed with cancer

Summary:

The Jerusalem Post published an article titled, “A cure for cancer?  Israeli scientists may have found one.” The story profiled a small Israeli company called Accelerated Evolution Biotechnologies that has been working on developing new cancer treatments since 2000. The article relied almost entirely on an interview with the company’s chairperson of the board who made a series of unsubstantiated claims that included that, in a year’s time, the company will offer a complete cure for cancer. (2/12/19)

Relevance: High

Relevance

Quality of Writing: High

Quality of Writing

Article: The cost of cancer care and impact of financial hardship on treatment

Most relevant for: Anyone diagnosed with cancer

Summary:

Several recent studies on the cost of cancer care show the negative effects on cancer patients. In this XRAYS we review a recent article by Kaiser Health News and associated studies about the financial impact of breast cancer treatment and cost of precision medicine. (2/8/19)

Relevance: High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: The impact of palbociclib (Ibrance) on overall survival for metastatic breast cancer patients in the PALOMA-3 trial

Most relevant for: People with metastatic, hormone-positive breast cancer

Summary: 

The PALOMA-3 clinical trial showed that a new CDK4/6 inhibitor in combination therapy improved progression-free survival of women treated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women with prior disease progression after endocrine therapy. This XRAYS reviews a newly published study in the New England Journal of Medicine that looks at overall survival in the original PALOMA-3 study. (1/23/19)

Relevance: Medium-High

Relevance

Strength of Science: High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Inherited breast cancer in Nigerian women

Most relevant for: Nigerian women or women of Nigerian descent who have breast cancer

A new study shows that among Nigerian women, one in eight cases of breast cancer is due to an inherited mutation in BRCA1, BRCA2, PALB2 or TP53. (12/5/18)

Relevance: High

Relevance

Strength of Science: High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Can population-based DNA sequencing find more people at risk for hereditary cancers?

Most relevant for: Women over age 30

It is well documented that many BRCA mutation carriers are missed using current family history-based screening approaches. As a result, experts are beginning to call for population-based BRCA genetic testing—an organized effort to screen all women like we do for breast and cervical cancer.  A recent study looked at whether a population-based genetic testing approach would better identify mutation carriers compared with current practice. (11/17/18)

Relevance: High

Relevance

Quality of Writing: High

Quality of Writing

Article: The importance of racial diversity in clinical trials

Most relevant for: People who are a member of a racial or ethnic minority group

This article by journalists Caroline Chen and Riley Wong looks at racial disparities between participation in clinical trials and the population of people with cancer. (11/6/18)

Relevance: High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Surgeon attitude impacts rate of genetic testing after a breast cancer diagnosis

Most relevant for: Young women diagnosed with breast cancer who have not yet had genetic testing

A study in JAMA Surgery this year examined the factors that impact genetic testing after a breast cancer diagnosis. This study suggests that the attitudes of attending surgeons about genetic testing have the most impact on whether patients receive testing. (10/6/18)

Relevance: Medium-Low

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: A new method for determining whether genetic variants in BRCA1 increase cancer risk

Most relevant for: People who have a Variant of Uncertain Significance in a gene associated with cancer risk.

Ever since BRCA1 was discovered, researchers have been trying to understand which of the thousands of possible DNA changes in this gene increase cancer risk and which are harmless changes.  A new study in Nature reports how a cutting-edge technology called “genome editing” may be used to classify changes—known as variants of uncertain significance-in BRCA1 as harmful or harmless. Once validated, this same technology may be used to classify variants in other genes. (9/29/18)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Gardening improves health outcomes for breast cancer patients

Most relevant for: People diagnosed with breast cancer who would benefit from increased activity and from eating more vegetables

Research has shown that adopting a healthier lifestyle may improve overall health and outcomes for cancer survivors. This study looked at a 1-year home-based gardening intervention to increase activity and wellbeing among breast cancer survivors. (08/31/18)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Study identifies genes associated with risk of triple-negative breast cancer

Most relevant for: People diagnosed with triple-negative breast cancer

Panel testing can identify women who are at increased risk for breast cancer.  However, those at risk for triple-negative breast cancer cannot easily be identified because other than BRCA1, genes that increase the risk for triple-negative breast cancer are unknown.  A new study uses panel testing to identify which genes increase the risk for triple-negative breast cancer. (8/23/18)

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Immunotherapy may lead to long-term remission of metastatic breast cancer

Most relevant for: People with advanced cancers

Metastatic breast cancer is often difficult to treat. In a new approach, called adoptive cell therapy (ACT), a patient’s own T-cells (a type of cancer-fighting immune cells) are collected, multiplied in a lab, and then returned to the patient. The goal is to enhance the patient’s immune system with many more T-cells that recognize and attack metastasized tumor cells. This study reports on a single patient whose metastatic breast cancer is still in remission (no evidence of disease) after more than 22 months following ACT. (8/16/18)

Relevance: High

Relevance

Quality of Writing: High

Quality of Writing

Article: High health insurance deductibles can interfere with breast cancer treatment decisions

Most relevant for: People diagnosed with breast cancer

A New York Times article published on May 4, 2018 examines the impact of high insurance deductibles on breast cancer treatment. (7/12/18)

Relevance: Medium

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations

Most relevant for: People who are considering or have had direct-to-consumer testing

A clinical genetic testing laboratory examined results from direct-to-consumer genetic testing ordered directly by patients. They found many instances of false positives—reported mutations that were not actually present—and in some cases, reports of variants that "increased risk," but were actually benign. This study emphasized the importance of involving genetics experts in the interpretation of genetic test results. (6/28/18)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Mutations in Lynch syndrome genes MSH6 and PMS2 may be associated with breast cancer

Most relevant for: Women with an MSH6 or PMS2 mutation

Some women with mutations in MSH6 and PMS2, two Lynch syndrome genes, may have a modest (2 to 3-fold) increased risk for breast cancer. (6/14/18 updated 09/25/19)

Relevance: Medium

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Metastasis is affected by wound healing and inflammation in study on mice

Most relevant for: Cancer patients who will be, or have recently undergone surgery

This study in mice looked at how wound healing after surgery affects metastasis. Researchers found that wound healing caused changes in the mouse immune system that allowed some cancer cells to grow, but that treatment with a non-steroidal anti-inflammatory drug (NSAID) reduced inflammation and frequency of metastases. While this research is promising, it remains to be seen if similar effects occur in humans. (5/17/18)

Relevance: Medium-High

Relevance

Guideline: American Heart Association examines the challenges of cardiovascular disease and breast cancer

Most relevant for: People diagnosed with breast cancer

Current breast cancer treatments can negatively affect cardiovascular health.  Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer.  This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)

Relevance: High

Relevance

Quality of Writing: High

Quality of Writing

Article: The right not to know when not knowing is dangerous

Most relevant for: People with Icelandic heritage

Healthcare providers are bound by the guiding principle of doing no harm. But how does this concept apply to their patients who have not consented to genetic testing or who do not want to know their results? In that case, is providing test results more harmful or not? Anna Clausen explores these issues in the context of breast cancer gene testing in her Global Health Now article “The Right Not to Know: When Ignorance is Bliss but Deadly.” (4/20/18)

Relevance: Medium

Relevance

Research Timeline: Post Approval

Research Timeline

Guideline: FDA approves at-home test kits for inherited cancer: how useful are they?

Most relevant for: People who are considering or have had direct-to-consumer testing through 23andMe

Interest in personalized genetic testing is growing. Genetic testing about health conditions typically requires a prescription from a health care provider. Until recently, the direct-to-consumer (DTC) testing market has focused on ancestry and discovery of unknown branches of family trees. A laboratory called 23andMe that provides direct-to-consumer genetic testing has been given FDA approval to report results for 3 mutations found in the BRCA1 and BRCA2 genes. The FDA statement provides details about this approval and cautions consumers about the limitations of the 23andMe test. (03/19/18)

Relevance: Low

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Study: Is asparagus linked to breast cancer metastasis?

Most relevant for: People diagnosed with breast cancer

A new study published in the journal Nature shows that asparagine, a protein building block that takes its name from asparagus, promotes the spread of breast cancer in mice. The study by cancer experts from Britain, Canada and the U.S. investigated whether limiting the levels of asparagine in mice could reduce tumor metastasis. (3/2/18)

Relevance: Medium-Low

Relevance

Strength of Science: Medium-Low

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Study: Cancer “vaccine” injected directly into tumors works in mice

Most relevant for: People with advanced cancers

Immunotherapy is treatment that uses the immune system to fight cancer. Still in its infancy, it is a promising therapy that is changing how certain cancers are treated. A new study reports that tumors in lab mice were eliminated when they were injected with two immune system-enhancing agents. This new approach is called in situ (at the original site) vaccination because the injections are given directly into the tumors. It worked on several different types of mouse tumors, including lymphomas and breast tumors. This approach may be safer than conventional immunotherapy because it uses very low doses of the agents and it does not require tumors to have particular markers. (02/23/18)

Relevance: Medium-High

Relevance

Quality of Writing: Medium-High

Quality of Writing

Article: Coping with the financial burden of breast cancer

Most relevant for: People diagnosed with breast cancer

U.S. News & World Report recently talked to three breast cancer survivors, including two young women, about how they handled out-of-pocket costs and other medical expenses after their cancer diagnosis. (Posted 1/4/18)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Genetic counseling by phone or face-to-face

Most relevant for: People referred to a genetic counselor or those considering genetic testing

Results presented at the 2017 American Psychological Association’s annual meeting showed genetic counseling by telephone is as “safe and effective” in long-term psychological and social outcomes compared to traditional in-person counseling for women at risk for hereditary breast and ovarian cancer. This presentation is an update on research published in 2014. (11/29/17)

Relevance: Medium

Relevance

Quality of Writing: Medium-High

Quality of Writing

Article: Mixed reviews of at-home genetic testing

Most relevant for: People who are considering or have had direct-to-consumer testing

National guidelines recommend that patients meet with a genetics expert before undergoing genetic testing for cancer risk. Genetic counseling can help patients decide whether genetic testing is right for them and order the most appropriate test. Once test results are available, genetics experts also help patients understand their results. Over the last decade, the popularity of direct-to-consumer (DTC) genetic testing, such as 23andMe has grown. Some genetic tests are marketed to consumers on television, in print advertisements, and on the Internet. These “at-home” genetic tests give people direct access to their genetic information without first involving a healthcare provider in the process. A recent report outlines the benefits and limitations of DTC genetic testing. (10/20/17)

Relevance: Medium-Low

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Study: Can chemotherapy before surgery fuel breast cancer metastasis?

Most relevant for: Newly diagnosed breast cancer patients

Some breast cancer patients are given neoadjuvant (before surgery) chemotherapy. However, some recent studies have raised concerns that neoadjuvant treatment might actually trigger cancer spread in certain situations. In the current study, researchers used mouse models and human breast cancers to explore this possibility. (10/10/17)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Does expanded genetic testing benefit Jewish women diagnosed with breast cancer?

Most relevant for: Jewish women with breast cancer who previously tested negative for the three most common BRCA mutations

BRCA1 and BRCA2 mutations are common in people of Eastern European (Ashkenazi) Jewish descent. About 2% of all Ashkenazi Jewish people will test positive for one of three common mutations in these genes. Genetic testing for Jewish people sometimes focuses on only the three most common mutations. For Jewish women with breast cancer, little is known about their chance of carrying a different hereditary mutation that may increase risk. This study looked at expanded genetic testing in Jewish women diagnosed with breast cancer to learn how often they carried mutations other than the three most common BRCA gene mutations found in Ashkenazi Jewish people. (09/13/17)

Relevance: Medium-High

Relevance

Quality of Writing: High

Quality of Writing

Article: Parents face challenges when deciding the best time to tell children that they may be at high risk for cancer

Most relevant for: Parents who have an inherited gene mutation

When certain types of cancers run in families, genetic testing can determine whether the cause is hereditary. Genetic testing can help family members understand their cancer risk and make medical decisions to stay healthy. A test result can provide significant insight, but it also creates challenges for parents, because gene mutations that cause hereditary cancers can be passed from mothers and fathers to sons and daughters. People with these mutations must make difficult decisions about when to tell their children that they too may have inherited the mutation. (8/22/2017)

Study: Immunotherapy shows promise in triple-negative breast cancer

Most relevant for:

THIS INFORMATION HAS BEEN UPDATED on 04/06/19: Based on published research studies, the FDA approved atezolizumab (Tecentriq) used in combination with the chemotherapy drug nab–paclitaxel (Abraxane) for women with locally advanced or metastatic triple-negative breast cancer that cannot be treated surgically and whose tumors are positive for a protein called PD-L1. The FDA also approved a companion diagnostic test called the VENTANA PD-L1 Assay, to identify patients with triple-negative breast cancer who are candidates for this treatment.

Patients diagnosed with triple-negative breast cancer (TNBC) do not have many treatment options. Immunotherapy, a new type of cancer treatment, pushes the body’s natural defense or immune system to fight cancer. A new immunotherapy drug, atezolizumab (Tecentriq) may improve survival for patients with metastatic TNBC. (07/11/17)  

Relevance: High

Relevance

Quality of Writing: High

Quality of Writing

Article: FDA busts myths of preventing and treating cancer by eating apricot kernels, herbs, and other ingredients

Most relevant for: People diagnosed with or concerned about their risk for cancer

Maggie Fox (NBC News) writes about a new FDA report that warns of 14 "fraudulent” cancer products claiming to either cure or treat cancer (1). The companies that sell these products claim that many of them also prevent cancer, but are they safe or effective? (6/26/17)

Relevance: High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Does scalp cooling help prevent hair loss after chemotherapy?

Most relevant for: Patient undergoing chemotherapy

Hair loss is one of the most recognized and distressing side effects of some chemotherapies. Two studies looked at the use of scalp cooling therapy to help reduce hair loss after chemotherapy for early-stage breast cancer. (5/15/17) 

Update: Based on data from clinical trials, the FDA approved Dignicap scalp cooling device for treatment in patients diagnosed with solid tumors who are receiving chemotherapy. 

Relevance: Medium-Low

Relevance

Strength of Science: Medium-Low

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Study: Common genetic change found in some tumors of patients who relapse after aromatase inhibitor treatment

Most relevant for: Patients with ER+ breast cancer

About one in five people diagnosed with estrogen receptor-positive (ER+) breast cancer relapse within 10 years after treatment. Researchers and health care providers do not know why this happens. This early research aims to identify a genetic change in the tumor that may cause relapse, but more studies are needed to understand why patients relapse and who is at risk. (5/3/17)

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Study: Does eating soy affect the risk of death in breast cancer survivors?

Most relevant for:

Is eating soy safe for people who have had breast cancer? This topic has been controversial among health care providers, patients, and survivors for many years because research has yielded mixed results. Some studies suggest people who have been diagnosed with breast cancer should eat more soy products, while other studies recommend they eat less or avoid it altogether. Which should it be? Adding to this research is a new study that asked breast cancer survivors about their soy consumption before and after diagnosis. (4/27/17)

Relevance: Medium-Low

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Article: Does metastasis happen earlier than previously thought?

Most relevant for:

Sharon Begley discusses an unconventional new idea about how cancer cells spread (a process known as metastasis) in her recent piece for the website STAT. She states that, “cancer cells spread way earlier than thought, seeding metastases that cause most deaths.” (3/28/17)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Study: Friends and family may help breast cancer survival

Most relevant for: People diagnosed with breast cancer

Does having a large social network help breast cancer survivors have better outcomes? Research from the current study found that socially isolated breast cancer survivors had an increased risk of recurrence and breast cancer-specific mortality. (3/16/17)

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Research suggests exercise is safe for breast cancer patients at risk for lymphedema

Most relevant for: People with, or at high risk for lymphedema after breast cancer

Patients and health care providers are often concerned about how exercise affects lymphedema (swelling in the arm or hand) in breast cancer survivors or other women who have had lymph node biopsy at the time of mastectomy. Research on this topic has been mixed. A new study suggests that exercise after breast cancer treatment does not lead to lymphedema or worsen existing lymphedema. However, because this study was small, more work needs to be done to understand the relationship between exercise and lymphedema in cancer survivors. (2/22/17)

Relevance: Medium-Low

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Lab Research

Research Timeline

Study: Hot chili pepper component slows growth and kills laboratory-grown breast cancer cells

Most relevant for: This research is not relevant to people yet

Finding new treatments that target triple-negative breast cancer is an area of great interest. An early step in developing these treatments is learning more about the biology of tumor in the laboratory. This study looked at how capsaicin, the spicy component of chili peppers, might work with a protein found in many cancers, including triple-negative breast cancer, to stop cancer cell growth. This is the first step in a long process towards developing new treatments for triple-negative breast cancer. (2/14/17)

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: High vitamin D levels at breast cancer diagnosis may be associated with a better prognosis

Most relevant for: Women at average risk for breast cancer and newly diagnosed women

Vitamin D is most known for its role in maintaining bone health but vitamin D has additional roles in keeping us healthy. In this study, researchers found that breast cancer patients who had the highest amounts of vitamin D in their blood (slightly over the recommended levels) had better health outcomes, including overall survival, than women with lower amounts of vitamin D. This finding adds to the growing evidence for the role of vitamin D in cancer, but it does not change how breast cancer is prevented or treated. (1/10/17)

Relevance: Medium-High

Relevance

Quality of Writing: Medium

Quality of Writing

Personal Story: Men get breast cancer too

Most relevant for: Men diagnosed with breast cancer

Cathy Free's piece for People, “Men Have Breasts Too: New York Man Who Survived Stage 2 Breast Cancer Spreads Message,” tells the stories of two men whose experiences with breast cancer inspired them to speak openly about breast cancer awareness for men. (11/29/16)

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Study: Cancer treatment costs can vary widely

Most relevant for: People diagnosed with breast cancer

Healthcare providers cannot give their breast cancer patients information on chemotherapy treatment costs because not enough is known about the exact costs. New research finds that costs vary not only between different cancer treatments, but also between similar treatments, such as all treatments that target HER2+ breast cancer. (11/22/16)

Relevance: Medium-High

Relevance

Quality of Writing: High

Quality of Writing

Personal Story: CBS News brings attention to the issues facing young metastatic breast cancer patients

Most relevant for: Women diagnosed with metastatic breast cancer

Beth Caldwell is a former civil rights lawyer, a mother of two, and a wife who was diagnosed with stage 4 metastatic breast cancer when she 37. Mary Brophy Marcus covered Beth’s story in her piece, “The hardest part” of breast cancer under 40, for CBS News. (11/8/16)

Relevance: Medium

Relevance

Strength of Science: Medium

Strength of Science

Study: Breast cancer mortality among Hispanic women in the United States varies by country of origin

Most relevant for:

"Hispanic" is a broad ethnic category that includes people from numerous countries. When discussing breast cancer statistics, Mexicans, Cubans, Puerto Ricans and people whose families originated in Central and South America are typically grouped into one Hispanic category. A new study looked at whether the country of origin affected breast cancer prevalence and mortality rates in Hispanic women in the U.S. (10/25/16)

Relevance: High

Relevance

Quality of Writing: High

Quality of Writing

Article: Huffington Post article brings attention to metastatic breast cancer

Most relevant for: People diagnosed with metastatic breast cancer

Barbara Jacoby's Huffington Post piece, "How do breast cancer and metastatic breast cancer differ?" emphasizes the need for more treatment options for patients with advanced breast cancer.

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?

Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study

As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)

Relevance: Medium

Relevance

Quality of Writing: High

Quality of Writing

Article: A cancer patient’s tumor is genetically profiled—how does that info help treatment?

Most relevant for: People diagnosed with advanced cancer

Jessica Wapner's Scientific American article explores the difficulties of making the vast amount of information acquired from tumor gene tests useful to patients and physicians. (9/20/16). Update: THIS INFORMATION HAS BEEN UPDATED. In late 2017, the FDA approved two separate tumor profiling tests to help guide treatment choices. The FoundationOne CDx (F1CDx) genomic test has been approved to test for 15 different targeted therapies used to treat five types of cancer, including ovarian, colorectal, lung, breast and melanoma. The FDA also approved the MSK-IMPACT and developed for use by Memorial Sloan Kettering Cancer Center (MSKCC) to scan tumor samples for 468 different cancer-associated mutations or alterations.

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Human Research

Research Timeline

Study: Can acupressure be used to treat cancer-related fatigue?

Most relevant for: Breast cancer survivors and people in treatment who are experiencing fatigue

Breast cancer survivors commonly report experiencing considerable fatigue, which can lead to sleep problems and poor quality of life. Yet, there are no good therapies for these patients. This research study looks at whether self-administered acupressure can help breast cancer survivors with their fatigue. (8/9/16)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Racial disparities in BRCA testing: Why?

Most relevant for: African American women who have been diagnosed with breast cancer

Black women receive BRCA testing less frequently than white women. Why is that? Researchers thought the reason might be that black and white women see different health care providers. However, new research suggests that disparities in physician recommendations for testing are the cause: black women with breast cancer were less likely to receive physician recommendations for BRCA testing than white women with breast cancer. There is a need to ensure equity in physician testing recommendations for black women. (7/21/16)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Study: Financial burden affects quality of life of cancer survivors

Most relevant for: People diagnosed with cancer

Cancer-related financial burden can keep survivors from getting the care that they need, yet how this burden affects mental and physical health is still unknown. A study found that almost one-third of cancer survivors report having financial burden; those most likely to be affected were under age 65, female, members of racial or ethnic minority groups, and people who lack access to adequate insurance. (5/17/16)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Study: Factors that affect the ability to work in people with metastatic cancer

Most relevant for: People living with metastatic cancer

Some patients who live with metastatic cancer either want or need to continue working while coping with symptoms of their disease and treatment. A recent study that looked at over 600 people with metastatic breast, prostate, colon, or lung cancer found that about one-third of them continue working full or part time. People most likely to continue working were those undergoing hormonal treatment and those with less severe symptoms or side effects from treatment. (4/12/16)

Relevance: Medium

Relevance

Quality of Writing: Medium-Low

Quality of Writing

Article: New York Times report demonstrates need for genetic counseling, but doesn’t give the whole story

Most relevant for: People diagnosed with breast cancer

A New York Times report discussed how genetic testing could provide “grim data” without guidance for patients. While this is a valid concern, this report does not sufficiently emphasize certain important issues regarding genetic testing, particularly the need for genetic counseling by a health care provider with expertise in genetics before and after genetic testing. (4/5/16)

Relevance: Medium

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: What are the genetics underlying 12 different cancer types?

Most relevant for: People diagnosed with cancer

As gene sequencing has become more affordable, researchers and health care providers are now looking for mutations in many genes beyond BRCA1, BRCA2 and others that are associated with known hereditary cancer syndromes. By sequencing thousands of genes rather than just one or two, researchers can better understand which inherited mutations affect cancer risk. In this study, researchers sequenced thousands of genes in patients with one of 12 cancers, including breast, and catalogued which gene mutations are most commonly found in each cancer. (03/01/16)

Relevance: Medium-High

Relevance

Strength of Science: Medium-High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: Smoking before or after a breast cancer diagnosis associated with poorer breast cancer survival

Most relevant for: People who smoke cigarettes

Cigarette smoking is an important public health issue that causes more than 480,000 deaths annually. Smoking increases the risk of many diseases, from heart disease to stroke. This research indicates that smoking before and or after a diagnosis of breast cancer affects survival, and also shows that it is never too late to quit smoking. (02/23/16)

Relevance: Medium

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Study: Sugar promotes tumor growth and metastasis in mouse model breast cancer

Most relevant for: People diagnosed with breast cancer

Previous human studies found associations between high sugar intake and breast cancer risk. This study looked at the direct effect of sugar on breast cancer growth and metastasis in mice. While researchers observed that sugar increased tumor growth and metastasis, more work needs to be done to see if this finding is relevant in humans. It is important to remember, the overall health benefits of limiting sugar intake remain undisputed. (02/02/16)

Relevance: Low

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Animal Studies

Research Timeline

Study: Do antioxidants encourage the spread of cancer cells?

Most relevant for: The clinical relevance of this study for people is not clear

Scientists do not yet know why some cancers spread to other parts of the body (a process called metastasis). A study in mice suggested that high doses of some antioxidants (chemicals that can protect cells from damage) might actually make it easier for cancer cells to spread. (12/01/2015)

Relevance: Low

Relevance

Quality of Writing: Low

Quality of Writing

Article: What “The Truth About Cancer” got wrong about BRCA mutations and cancer

Most relevant for:

A website called thetruthaboutcancer.com, created a 9-part docu-series titled “The Truth About Cancer: A Global Quest” (TACGQ). The video states that Angelina Jolie’s decision to remove her breasts was one made out of fear; one commentator states that her decision was “barbaric." This video  contains a lot of dangerous misinformation about BRCA mutations and inherited cancer. FORCE XRAYS provides the following point-by-point analysis on "The Truth About Cancer." (11/10/2015)

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Study: Impact of familial breast cancer risk on young girls

Most relevant for: Young women and girls from high-risk breast cancer families

Does growing up in a family that is at high risk for breast cancer affect young girls? Recent research found girls from families with BRCA mutations and/or a strong family history of cancer to be as well adjusted as peers of the same age. The one difference was that girls from families facing breast cancer risk had more stress related to breast cancer than their peers. While these findings are reassuring, parents know their children best, and they should ask for help if they believe their daughters are not coping well. (11/03/2015)

Relevance: High

Relevance

Strength of Science: High

Strength of Science

Research Timeline: Post Approval

Research Timeline

Study: BRCA mutations more common than expected in young black women with breast cancer

Most relevant for: Young black women who have been diagnosed with breast cancer

Most estimates of the percentage of breast cancer patients with mutations in BRCA are based on studies in white women. These researchers found that black women diagnosed at a young age with breast were twice as likely to have a BRCA mutation than previously reported based on studies in white women with breast cancer diagnosed in the same age categories. This study shows how important it is for all black women diagnosed with invasive breast cancer at or before age 50 to be referred for genetic counseling and testing. (9/29/15)

This program was made possible by the generous support of:

Novartis

Search XRAY studies and articles

Back to XRAY Home

FORCE:Facing Our Risk of Cancer Empowered